<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00861094</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000595050</org_study_id>
    <secondary_id>FRE-FNCLCC- ACCORD-17-0707</secondary_id>
    <secondary_id>EU-20848</secondary_id>
    <nct_id>NCT00861094</nct_id>
  </id_info>
  <brief_title>Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer</brief_title>
  <official_title>Phase II-III Study Comparing Radiochemotherapy With the FOLFOX Regimen Versus Radiochemotherapy With 5FU-cisplatin (Herskovic Regimen) in First Line Treatment of Patients With Inoperable Oesophageal Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in
      chemotherapy, such as oxaliplatin, fluorouracil, leucovorin, and cisplatin, work in different
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
      dividing. Giving more than one drug (combination chemotherapy) together with radiation
      therapy may kill more tumor cells.

      PURPOSE: This randomized phase II/III trial is studying radiation therapy and two different
      combination chemotherapy regimens to compare how well they work as first-line therapy in
      treating patients with esophageal cancer that cannot be removed by surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To assess the feasibility of radiochemotherapy comprising oxaliplatin, fluorouracil, and
           leucovorin calcium (FOLFOX regimen) vs fluorouracil and cisplatin (Herskovic regimen) in
           patients with inoperable esophageal cancer. (Phase II)

        -  To assess the endoscopic complete response rate in patients treated with these regimens.
           (Phase II)

        -  To compare the event-free survival of patients treated with these regimens. (Phase III)

      Secondary

        -  To assess the toxicity profile of these regimens using the NCI CTC v2.0 criteria. (Phase
           II)

        -  To compare the overall survival, endoscopic complete response rate, incidence of grade
           3-4 toxicities, and time to treatment failure in patients treated with these regimens.
           (Phase III)

        -  To evaluate the quality of life of these patients using EORTC QLQ-C30 (version 3) and a
           validated disease-specific module EORTC QLQ-OES18. (Phase III)

      OUTLINE: This is a multicenter study. Patients are stratified according to histological type
      (adenocarcinoma or adenosquamous carcinoma vs squamous cell carcinoma), pretreatment weight
      loss within the past 6 months (grade 1 [&lt; 10%] vs grade 2 [≥ 10%]), ECOG performance status
      (0 vs 1 vs 2), and participating center. Patients are randomized to 1 of 2 treatment arms.

        -  Arm I (modified FOLFOX 4 regimen): Patients undergo radiotherapy 5 days a week for 5
           weeks. Beginning concurrently with radiotherapy, patients receive oxaliplatin IV over 2
           hours and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously
           over 46 hours on days 1 and 2. Treatment with chemotherapy repeats every 2 weeks for up
           to 6 courses in the absence of disease progression or unacceptable toxicity.

        -  Arm II (Herskovic regimen): Patients undergo radiotherapy as in arm I. Patients also
           receive cisplatin IV continuously over 24 hours on day 1 and fluorouracil IV
           continuously over 96 hours on days 1-4 of weeks 1, 5, 8, and 11 in the absence of
           disease progression or unacceptable toxicity.

      Quality of life is assessed at baseline, periodically during study therapy, and then every 6
      months for 1 year and annually for 3 years after completion of study therapy.

      After completion of study therapy, patients are followed at 4 weeks and then every 3-6 months
      until disease progression.

      PROJECTED ACCRUAL: A total of 97 patients will be accrued for the phase II portion of the
      study. A total of 169 patients will be accrued for the phase III portion of the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients who complete the full study treatment (Phase II)</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Endoscopic complete response rate (Phase II)</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival (Phase III)</measure>
    <time_frame>Until progression</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety profile as assessed by NCI CTC v2.0 (Phase II)</measure>
    <time_frame>Total duration of the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (Phase III)</measure>
    <time_frame>Total duration of the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response rate (Phase III)</measure>
    <time_frame>Total duration of the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure (Phase III)</measure>
    <time_frame>Total duration of the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of grade 3-4 toxicities (Phase III)</measure>
    <time_frame>Total duration of the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as assessed by EORTC QLQ-C30 (version 3) and EORTC QLQ-OES18 (Phase III)</measure>
    <time_frame>Total duration of the trial</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">266</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>FOLFOX and radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxaliplatin (85mg/m2); Folinic Acid (200mg/m2); 5-FU (400mg/m2-Bolus and 1600mg/m2 over 46h)- once every two weeks for six cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5-FU / cisplatin and radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5-FU (100mg/m2); Cisplatin (75mg/m2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <arm_group_label>5-FU / cisplatin and radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <arm_group_label>FOLFOX and radiotherapy</arm_group_label>
    <arm_group_label>5-FU / cisplatin and radiotherapy</arm_group_label>
    <other_name>5-Fluorouracil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <arm_group_label>FOLFOX and radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <arm_group_label>FOLFOX and radiotherapy</arm_group_label>
    <arm_group_label>5-FU / cisplatin and radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folinic Acid</intervention_name>
    <arm_group_label>FOLFOX and radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically proven adenocarcinoma, squamous cell carcinoma, or adenosquamous
             carcinoma of the esophagus

               -  Locally advanced disease (any T, N0 or N1, M0 or M1a)

                    -  No metastatic disease, except for tumor involvement of the upper third of
                       the esophagus or cervical esophageal tumor with regional nodes, or tumor
                       involvement of the lower third of the esophagus with celiac nodes (M1a)

                         -  Cervical primary tumor with positive supraclavicular or cervical lymph
                            nodes (defined as N1) allowed

                         -  No radiographic evidence of enlarged (≥ 1.5 cm) celiac lymph nodes by
                            CT scan or echography

               -  No small cell or undifferentiated carcinoma of the esophagus

               -  No multiple carcinomas of the esophagus (i.e., &gt; 1 esophageal tumor)

               -  No cardia tumor (Siewert II) or gastric tumor extension to the esophagus (Siewert
                  III)

                    -  Esophageal tumor extension to the cardia (Siewert I) (center of the tumor
                       lying &gt; 1 cm-5 cm above gastroesophageal junction) allowed

          -  Inoperable disease OR surgery is contraindicated

          -  No tracheo-esophageal fistula or invasion of the tracheo-bronchial tree

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Life expectancy ≥ 3 months

          -  Absolute neutrophil count ≥ 1,500/mm³

          -  Platelet count ≥ 100,000/mm³

          -  Hemoglobin ≥ 10 g/dL (transfusion allowed)

          -  Creatinine &lt; 15 mg/L

          -  Total bilirubin &lt; 1.5 times upper limit of normal (ULN)

          -  ALT and AST &lt; 2.5 times ULN

          -  Prothrombin time ≥ 60%

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  Caloric intake sufficient (i.e., &gt; 1,000 Kcal/m²/day) (orally or with gastrostomy)

          -  No weight loss &gt; 20% normal body weight within the past 3 months

          -  No complete dysphagia

          -  No exclusive requirement for parenteral nutrition

          -  No peripheral neuropathy &gt; grade 1

               -  No sensitive peripheral neuropathy with functional impairment

          -  No auditory disorders

          -  No other prior malignancies except curatively treated nonmelanoma skin cancer or
             carcinoma in situ of the cervix or stage I or II node-negative head and neck cancer
             that was curatively treated &gt; 3 years ago

          -  No myocardial infarction within the past 6 months

               -  Patients who have had a myocardial infarction &gt; 6 months ago are eligible
                  provided there is no transient ischemia by thallium myocardial scintigraphy and
                  patient is able to undergo chemotherapy , as determined by a cardiologist

          -  No other serious illness or medical condition (e.g., symptomatic coronary disease,
             left ventricular failure, or uncontrolled infection)

          -  No stage II-IV arterial disease, according to the DE LERICHE and FONTAINE
             classification

          -  No geographical, social, or psychological circumstances preventing regular follow-up

        PRIOR CONCURRENT THERAPY:

          -  No prior treatment for esophageal cancer (e.g., surgery, chemotherapy, or
             radiotherapy)

          -  No prior cervical, thoracic, or abdominal radiotherapy with field overlapping the
             proposed esophageal radiotherapy field

          -  More than 30 days since prior experimental drugs or participation in another clinical
             trial

          -  No other concurrent anticancer therapy

          -  No concurrent phenytoin or yellow fever vaccine

          -  No concurrent high-dose, long-term corticosteroids

          -  No concurrent calcium gluconate/magnesium sulfate infusions

          -  No concurrent hematopoietic growth factors

          -  No concurrent esophageal dilatation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thierry Conroy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Alexis Vautrin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHR de Besancon - Hopital Saint-Jacques</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Andre</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Ambroise Pare</name>
      <address>
        <city>Boulogne-Billancourt</city>
        <zip>F-92104</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique Du Parc</name>
      <address>
        <city>Caen</city>
        <zip>14052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Du Bocage</name>
      <address>
        <city>Dijon</city>
        <zip>21034</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Lutte Contre le Cancer Georges-Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospital Regional Universitaire de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Europeen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <zip>51056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU - Robert Debre</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Armoricaine De Radiologie</name>
      <address>
        <city>Saint Brieuc</city>
        <zip>F-22015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Du Parc</name>
      <address>
        <city>Toulouse</city>
        <zip>31078</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre-les-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>F-94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2009</study_first_submitted>
  <study_first_submitted_qc>March 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2009</study_first_posted>
  <last_update_submitted>December 17, 2015</last_update_submitted>
  <last_update_submitted_qc>December 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the esophagus</keyword>
  <keyword>squamous cell carcinoma of the esophagus</keyword>
  <keyword>stage IIA esophageal cancer</keyword>
  <keyword>stage IIB esophageal cancer</keyword>
  <keyword>stage IIIA esophageal cancer</keyword>
  <keyword>stage IIIB esophageal cancer</keyword>
  <keyword>stage IIIC esophageal cancer</keyword>
  <keyword>stage IV esophageal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

